ADHD in Children and Adults: Diagnosis and Comorbidity Issues
Thomas J. Spencer, MD Assistant Chief, Pediatric Psychopharmacology Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School Boston, Massachusetts
There is no charge for participating in this educational activity. Term of Offering:  CME credit for this archived Internet webcast program will be available through September 1, 2002. The original release of this material was June 4th, 2001. CME credit is offered upon successful completion of the post-test.

Faculty Biography Thomas J. Spencer, MD Dr. Thomas J. Spencer is associate professor of psychiatry at Harvard Medical School and assistant director of the Pediatric Psychopharmacology Research Program at Massachusetts General Hospital. Dr. Spencer’s research and clinical interests have focused on the effectiveness and safety of standard and novel pharmacological treatments of ADHD throughout the lifecycle. Dr. Spencer has published numerous articles and book chapters and is on the Editorial Board of a number of journals.

Back to Top

Learning Objectives

After completion of this program, participants should be able to:

• Describe the prevalence, epidemiology, and natural course of ADHD as a disease
• Identify clinical diagnostic features of ADHD in children and adults
• Compare the clinical manifestations of ADHD with other comorbid conditions encountered in these patients
• Describe the benefits of therapy on health outcomes in patients with ADHD

Back to Top

Faculty Disclosure

Thomas J. Spencer, MD 
Grants, speakers’ bureau, consultant: Abbott Laboratories; Alza Pharmaceuticals; Boston Life Sciences; Bristol-Myers Squibb Company; Eisai Inc.; Glaxo Wellcome Inc.; Gliatech Inc.; Eli Lilly and Company; Medeva Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Shire Richwood Inc.; SmithKline Beecham; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Pharmaceuticals. 

Back to Top